ロード中...

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

AIMS: The Medical Research Council OVO5/EORTC 55955 trial showed that patients in remission after first-line therapy for ovarian cancer did not benefit from routine measurement of CA125 during follow-up. Since the presentation of these results, we have counseled patients about the options for follow...

詳細記述

保存先:
書誌詳細
出版年:Int J Gynecol Cancer
主要な著者: Krell, Daniel, Said Battistino, Fran, Benafif, Sarah, Ganegoda, Lochani, Hall, Marcia, Rustin, Gordon J.S.
フォーマット: Artigo
言語:Inglês
出版事項: Lippincott Williams & Wilkins 2017
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5499967/
https://ncbi.nlm.nih.gov/pubmed/28333841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000956
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!